Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide

Cancer Investigation

Volumn 31, Issue 3, 2013, Pages 190-196

  Batisse, Marie ^a,b   Raverot, Gérald ^c,d   Maqdasy, Salwan ^a,b   Durando, Xavier ^d,e   Sturm, Nathalie ^d,f,g   Montoriol, Pierre François ^a   Kemeny, Jean Louis ^a   Chazal, Jean ^a   Trouillas, Jacqueline ^c,d   Tauveron, Igor ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b Faculté de Médecine   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d INSERM   (France)

^e Jean Perrin Centre   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Aggressive pituitary adenoma; MGMT; Silent GH adenoma; Temozolomide treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; GROWTH HORMONE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OCTREOTIDE; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CLINICAL ARTICLE; DIPLOPIA; DISEASE SEVERITY; GENE EXPRESSION; GROWTH HORMONE SECRETING ADENOMA; HEADACHE; HUMAN; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMOTER REGION; PTOSIS; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; HUMAN GROWTH HORMONE; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84875034854     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2013.775293     Document Type: Article

References (28)

1. Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:543-554.
2. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER, Jr. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011;114:336-344.
3. Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine 2005;28:27-35.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
5. KulkeMH, Stuart K, Enzinger PC, Ryan DP, Clark JW, MuzikanskyA, Vincitore M,MicheliniA, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406.
6. Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010;95:4592-4599.
7. Sheehan J, Rainey J, Nguyen J, Grimsdale R, Han S. Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg 2010;114:354-358.
8. Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011;117:454-462.
9. Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010;163:843-851.
10. Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 2010;95:E280-E290.
11. Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012;76:769- 775.
12. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009;161:631-637.
13. Morin E, Berthelet F,Weisnagel J, Bidlingmaier M, Serri O. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2010;15:97-100.
14. McCormack AI, McDonald KL, Gill AJ, et al. Low O6- methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009;71:226-233.
15. Trouillas J, Sassolas G, Loras B, et al. Somatotropic adenomas without acromegaly. Pathol Res Pract 1991;187:943-949.
16. Wade AN, Baccon J, Grady MS, Judy KD, O'Rourke DM, Snyder PJ. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011;165:39-44.
17. Erickson D, Scheithauer B, Atkinson J, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2009;71:92-99.
18. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 2010;13:367-379.
19. Raverot G, Wierinckx A, Jouanneau E, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol 2010;163:35-43.
20. Mindermann T, Kovacs K, Wilson CB. Changes in the immunophenotype of recurrent pituitary adenomas. Neurosurgery 1994;35:39-44.
21. Daems T, Verhelst J, Michotte A, Abrams P, De Ridder D, Abs R. Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 2009;12:80-86.
22. Shimon I, Melmed S. Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997;82: 1675-1681.
23. Pinto EM, Siqueira SA, Cukier P, Fragoso MC, Lin CJ, de Mendonca BB. Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome. Pituitary 2009;14:400-404.
24. Lania AG, Ferrero S, Pivonello R, et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 2010;95:13-17.
25. Zuhur SS, Tanik C, Karaman O, et al. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine 2011;40:222-227.
26. Neidle S,Thurston DE. Chemical approaches to the discovery and development of cancer therapies.Nat Rev Cancer 2005;5:285-296.
27. Salehi F, Scheithauer BW,Kros JM, et al.MGMTpromoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 2011;104:647-657.
28. Heaney AP. Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 2011;96:3649-3660.